LRM

Quote






















































Maybe I'm unique, but the LRM was a good meeting. Over the years, I've launched over summer vacation, the holidays, etc. - they always seem to interrupt personal plans of one sort or another. Also, I'm not sure what you've heard over the past several months, but there is quite an appetite for this product. If we're looking for something to complain about, we'll always find it, but I think we have a great upside here both in pain and beyond.
 






anonymous said:
Maybe I'm unique, but the LRM was a good meeting. Over the years, I've launched over summer vacation, the holidays, etc. - they always seem to interrupt personal plans of one sort or another. Also, I'm not sure what you've heard over the past several months, but there is quite an appetite for this product. If we're looking for something to complain about, we'll always find it, but I think we have a great upside here both in pain and beyond.
Click to expand...
You are unique, there are appetites for all new drugs that hit the market. It’s all about health insurers allowing their “lives” to get them. You can live in your overly optimistic bubble, this is going to be an uphill battle due to cost and data showing equivalency to placebo.
 






This continues to be a potential game changer. This site does bring out the worst of opinions, and this seems to be no different. Pessimism and negativity has never led to any level of success. I loved the meeting - so good to see the rest of the team and have the extra time with the material.
 












I thought it was as good a meeting as it could have been given the unknowns. As for bonus? They've been paying us for 6 months and we've brought in zero in sales. Quit crying. Now the data is concerning. Side effect profile is outstanding but we are selling it for pain and it works no better than a wimpy opioid dose and tied with placebo. We will need stronger and more data on efficacy in pain and a strong message on the fact high placebo responses in pain studies are common. To pretend these aren't issues is foolish. And if patients are truly our first priority then they need to go far deeper on the opioid crisis to wake people up who are prescribing but haven't lived through having a loved one destroyed by opioids. Great company. Great science. But this is a new space and some bumps are hitting that need fixed.
 






anonymous said:
Manager here. If you don’t like it here, leave! Get out. We don’t need your negativity.
Click to expand...
Typical manager response, sees the highlighting of a legitimate issue as a negative. “Ignore that data and just get out there and make your 15 calls per day”
Stay positive even though all this writing is on the wall. BTW, this response shows how frustrated you actually are. “Manager here”, idiot.
 






Nothing says, "not really a manager" like starting a message with "manager here". The leaders that I have interacted with as a group and personally have been outstanding. Earlier poster makes a good point, there are so many tailwinds that will accelerate this launch. Issues are to be expected, and those will certainly be managed over time. It is also important to focus on the acute claim - it is so clean, and the support for patients is outstanding. I have been with so many companies who neglect this aspect and hope for coverage, it is amazing to see the support here. Also, the number of follow on studies and products is inspiring. Nothing is ever perfect, but upside of the science and potential significant this year and in future years.
 






I agree with the posts above, and am not sure where the negativity is coming from (probably trolls outside the company). I love my manager, director, team, and the vertex vibe. More so I really love the potential and look forward to delivering for patients today and in the years to come.
 






anonymous said:
I agree with the posts above, and am not sure where the negativity is coming from (probably trolls outside the company). I love my manager, director, team, and the vertex vibe. More so I really love the potential and look forward to delivering for patients today and in the years to come.
Click to expand...
Executive leadership is new to leading sales and will need to grow into the role to keep people. You can not build a lean sales team and then treat them poorly without very disruptive attrition in MSAs. This is a seasoned sales force that has had little input on how things are developing in preparation for launch. It honestly doesn't take much more effort to to treat people like they matter. Most will stay and will work tirelessly to change the course of pain therapy until the sign on is outside the payback window. The therapy will be special, Vertex is not.
 






Overly positive comments coming from those who made a move for a big salary are predictable. Of course you will make claims about science and company “vibe” being outstanding to save face. Pay attention to that feeling in your gut, you are smart enough to know what it is telling you. The developments over the last year have not been helpful. A much harder road to travel looms ahead for all.
 






anonymous said:
I thought it was as good a meeting as it could have been given the unknowns. As for bonus? They've been paying us for 6 months and we've brought in zero in sales. Quit crying. Now the data is concerning. Side effect profile is outstanding but we are selling it for pain and it works no better than a wimpy opioid dose and tied with placebo. We will need stronger and more data on efficacy in pain and a strong message on the fact high placebo responses in pain studies are common. To pretend these aren't issues is foolish. And if patients are truly our first priority then they need to go far deeper on the opioid crisis to wake people up who are prescribing but haven't lived through having a loved one destroyed by opioids. Great company. Great science. But this is a new space and some bumps are hitting that need fixed.
Click to expand...
When you find yourself defending your drug’s outcomes compared to the PLACEBOS - you have a serious problem
 






Top Bottom
Back
Quote